Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Phase II Reactions: Methylation Reactions

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pemphigoid gestationis and anti-SAE2-positive inflammatory myopathy without cutaneous involvement following assisted reproductive technology pregnancy: a rare autoimmune association.

Italian journal of dermatology and venereology·2026

Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026

Same author

Patient phenotyping to guide therapeutic strategies in bullous pemphigoid: towards personalized medicine in autoimmune bullous diseases.

The British journal of dermatology·2026

Same author

Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series.

Life (Basel, Switzerland)·2026

Same author

Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study.

Clinical and experimental dermatology·2026

Same author

Hand Edema and waxy papular eruption: a dermatologic riddle.

Clinical and experimental dermatology·2026

Search research articles

Related Experiment Videos

Hailey-Hailey disease treated with methotrexate.

Antonietta D'Errico¹, Diletta Bonciani, Veronica Bonciolini

¹Department of Medical and Surgical Critical Care, Section of Dermatology, University of Florence, Florence, Italy.

Journal of Dermatological Case Reports

|July 25, 2012

Summary

Methotrexate is a potential treatment for Hailey-Hailey disease (HHD), a chronic blistering condition. This study found it effective for a patient unresponsive to other therapies, suggesting it for long-term management.

Keywords:

Hailey-Hailey disease methotrexate pemphigus

Related Experiment Videos

Area of Science:

Dermatology
Immunology

Background:

Hailey-Hailey disease (HHD) is a chronic, recurrent blistering disorder.
Characterized by erosions in intertriginous regions and suprabasal acantholysis.
Often presents a therapeutic challenge due to resistance to conventional treatments.

Observation:

A long-standing case of HHD initially unresponsive to cyclosporine and steroids was reported.
Treatment with methotrexate (7.5 mg weekly for 16 weeks) yielded a good response.
Topical steroids were used as needed for symptom management.

Findings:

Methotrexate demonstrated significant efficacy in managing a refractory HHD case.
Intramuscular methotrexate, combined with topical steroids, proved beneficial.
The treatment regimen was well-tolerated, leading to disease control.

Implications:

Methotrexate may be a viable therapeutic option for Hailey-Hailey disease.
It could serve as a valuable maintaining therapy to control disease flares.
Further research into methotrexate's role in HHD management is warranted.